Product Description
M-131 is an antibody drug conjugate being developed by FutureGen for the treatment of T-cell leukemia and lymphoma. (Sourced from: http://www.futuregenbiopharm.com/#/product/pipeline)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FutureGen
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|